Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of AT-100 in Preterm Neonates at Risk for BPD
NCT04662151Phase 1Completed
- Sponsor
- Airway Therapeutics
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of zelpultide alfa in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Airway Therapeutics. Primary endpoints: Number of participants with treatment-related adverse events at Day 28 and Incidence of BPD or death. Started Sep 2021; status: completed.
02
Drugs
zelpultide alfa
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT04662151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662151.